Medical Services

Clinical Trials at Englewood Hospital: Non-Hodgkins Lymphoma

Non-Hodgkins Lymphoma

- Please scroll down to view all studies -

EHMC IRB Study #: E-14-546

Principal Investigator:
Dr. Francis Forte
Tel: 201-568-5250
Email: doc40@verizon.net

Study Coordinator:
Audrey Ades
Tel: 201-894-3603
Email: audrey.ades@ehmc.com

Sponsor:
Alliance

Study Title:
E1412: Randomized Phase II Open Label Study of Lenalidomide + R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma.

Eligibility requirements:
Patients who are at least 18 years old with newly diagnosed CD20+ diffuse large B cell lymphoma. Patients must have adequate organ function and be previously untreated.

Study objectives:
To compare progression-free survival in diffuse large B cell lymphoma patients randomly assigned to RCHOP vs. R2CHOP (RCHOP + lenalidomide.)

Summary of procedures:
Patients will be randomized to receive either RCHOP or R2CHOP for six, 21-day cycles.

###

*Each listing only contains a summary of the study information. Please contact the Principal Investigator or Study Coordinator for the full details on a particular study.